Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc has demonstrated a strong performance, reporting a revenue of $98.6 million for the second quarter of 2025, marking a year-over-year growth of approximately 13%, with notable contributions from its wound care and surgical segments. The company is optimistic about future growth, increasing its revenue estimate for 2025 to $387.3 million, which reflects confidence in its expanding surgical business. Despite an increase of about 16% year-over-year in selling, general, and administrative expenses, driven by higher sales commissions and legal costs, the underlying growth in key product categories supports a positive financial trajectory.

Bears say

MiMedx Group Inc reported a decline in gross margin, decreasing to approximately 81% from 83% in the second quarter of 2025, attributed to production variances and product mix issues. Although the company maintains its guidance for low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, the potential for adverse changes in reimbursement rates from CMS raises significant concerns regarding future revenue stability. This combination of declining margins and the uncertainty surrounding reimbursement policies contributes to a negative outlook for MiMedx Group's stock.

MiMedx Group (MDXG) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 2 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.